Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Silviavirus phage V1SA19
- Development stage
- Preclinical
- Lead developer
- Hospices Civils de Lyon
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intraarticular, Intravenous, Topical
01
Overview
Silviavirus phage V1SA19 (also known as vB_SauM-V1SA19) is a strictly lytic bacteriophage belonging to the *Herelleviridae* family and the *Silviavirus* genus. It was isolated from wastewater in Lyon, France, by the PHAGEinLYON consortium and Hospices Civils de Lyon. V1SA19 is developed as a Phage Therapeutic Medicinal Product (PTMP) for the treatment of severe, multidrug-resistant *Staphylococcus aureus* infections, including methicillin-resistant *S. aureus* (MRSA) and ocular MRSA infections. It acts by specifically binding to and lysing *S. aureus* host cells. The phage is formulated in a patented multi-component excipient solution called PhageProtect and is produced under public Good Manufacturing Practice (GMP) standards by the French national public platform PHAG-ONE.
- Other names
- Staphylococcus aureus phage V1SA19Staphylococcus phage vB_SauM-V1SA19
02
Targets
TA (Teichoic acid)
Beyond the preview
Go deeper on Silviavirus phage V1SA19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Silviavirus phage V1SA19.